Pyxis Discovery
| Private | |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | 2003 |
| Founder 👔 | Dmitry Genis |
| Headquarters 🏙️ | Amsterdam, Netherlands |
Area served 🗺️ | |
Key people | Anna Rzepiela (CEO) |
| Members | |
Number of employees | |
| 🌐 Website | pyxis-discovery |
| 📇 Address | |
| 📞 telephone | |
Pyxis Discovery is a Dutch contract research organization (CRO) active in small-molecule drug discovery.[1][2] It provides research services to pharmaceutical and biotechnology companies.[3][4][5]
History
Pyxis Discovery was founded in 2003 in Delft, Netherlands, by Dmitry Genis.[6] Initially focused on computational chemistry and lead-like compound library design, the company supported efficient drug discovery processes.[7][8] In 2005, Pyxis collaborated with Galapagos NV, ZoBio BV, and Leiden University on an arthritis drug discovery program, funded by a €1.2 million grant from the Dutch Ministry of Economic Affairs, contributing expertise in computer-aided design of fragment-based compound libraries.[9][10][11] In 2008, Pyxis Discovery partnered with ZoBio and NewLink Genetics on a fragment-based drug discovery project.[12] In 2009, the company entered a collaboration with iThemba Pharmaceuticals to provide compound sourcing and synthesis services.[13]
Pyxis later developed the Chemonaut platform, a database of screening compounds, and expanded its work in macrocyclic chemistry.[11]
Operations
Pyxis Discovery operates as a contract research organization providing medicinal chemistry services for small molecule drug discovery.[3] Its work focuses on macrocyclic compound libraries, including for molecular glue design, protein-protein interaction inhibition, and cell-permeable or covalent macrocycles. The company's design incorporates elements from natural products and known drugs into macrocyclic scaffolds. Its production employs a green chemistry philosophy using miniaturization to reduce reagent consumption and waste.[1][2]
Research and publications
Pyxis Discovery has contributed to academic literature on compound library design, macrocycle chemical space, and permeability, often in collaboration with institutions like Boston University.[14][1] Key publications include:
- Verheij, H. J. P. et al. (2006). "Leadlikeness and structural diversity of synthetic screening libraries". Molecular Diversity, 10(3): 377–388. doi:10.1007/s11030-006-9040-6. (Affiliation: Pyxis Discovery, Delft).[7]
- Brown, L. E.; Rzepiela, A. A. et al. (2021). "Defining and navigating macrocycle chemical space". Chemical Science, 12(12): 4309–4328. doi:10.1039/D0SC05788F. (Affiliation: Pyxis Discovery, Delft for A. A. Rzepiela).[1]
- Rzepiela, A. A. et al. (2022). "Conformational Effects on the Passive Membrane Permeability of Synthetic Macrocycles". Journal of Medicinal Chemistry, 65(15): 10300–10317. doi:10.1021/acs.jmedchem.1c02090. (Affiliation: Pyxis Discovery, Delft for A. A. Rzepiela).[14]
- Kersten, R. D. et al. (2018). "Evaluating novel synthetic compounds active against Bacillus subtilis and Staphylococcus aureus biofilms". Scientific Reports, 8(1): 9171. doi:10.1038/s41598-018-27529-4. (Input from A. Rzepiela, Pyxis Discovery).[15]
References
- ↑ 1.0 1.1 1.2 1.3 Brown, L. E.; Rzepiela, A. A.; Zhang, W.; Whitty, A. (2021). "Defining and navigating macrocycle chemical space". Chemical Science. 12 (12): 4309–4328. doi:10.1039/d0sc05788f. PMC 8179434 Check
|pmc=value (help). PMID 34163695 Check|pmid=value (help). - ↑ 2.0 2.1 Rzepiela, Anna; Whitmore, Charlotte; Whitty, Adrian (2022). "Macrocycles as drug leads". Drug Discovery Today: Technologies. 43: 1–10. doi:10.1016/j.drudis.2022.103335 (inactive 25 January 2026). Retrieved 2025-12-08.
- ↑ 3.0 3.1 "Pyxis Discovery BV". chemeurope.com. Retrieved 2025-12-08.
- ↑ "Pyxis Discovery". SelectScience. Retrieved 2025-12-08.
- ↑ "Pyxis Discovery Netherlands - Customer Profile". Apps Run The World. Retrieved 2025-12-08.
- ↑ Jaarverslag STW 2011 (PDF). Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO). 2011. p. 47. Retrieved 2025-12-08. Search this book on
- ↑ 7.0 7.1 Verheij, H. J. P.; Langereis, S.; Wijtmans, M.; de Esch, I. J. P.; Lecchi, P.; Leurs, R. (2006). "Leadlikeness and structural diversity of synthetic screening libraries". Molecular Diversity. 10 (3): 377–388. doi:10.1007/s11030-006-9040-6. PMID 17031539.
- ↑ "ChemBridge Libraries Most "Lead-Like/Diverse" in Independent Study". Technology Networks. 2009-06-18. Retrieved 2025-12-08.
- ↑ "Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University collaborate in arthritis drug discovery program". Galapagos NV. 2005-08-10. Retrieved 2025-12-08.
- ↑ "Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University collaborate in arthritis drug discovery program". bionity.com. 2005-08-11. Retrieved 2025-12-08.
- ↑ 11.0 11.1 "Fragment Collections". Cambridge MedChem Consulting. Retrieved 2025-12-08.
- ↑ "Pyxis and ZoBio go Dutch in US drug discovery collaboration". Science Business. 2008-06-03. Retrieved 2025-12-08.
- ↑ "iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering". BioSpace. 2009-11-25. Retrieved 2025-12-08.
- ↑ 14.0 14.1 Rzepiela, Anna A.; Viarengo-Baker, L. A.; Tatarskii, V.; Kombarov, R.; Whitty, A. (2022). "Conformational Effects on the Passive Membrane Permeability of Synthetic Macrocycles". Journal of Medicinal Chemistry. 65 (15): 10300–10317. doi:10.1021/acs.jmedchem.1c02090. PMID 35861996 Check
|pmid=value (help). - ↑ Kersten, R. D.; van Berlo, R.; Schuler, M.; Berger, M.; Verpoorte, R.; van Wezel, G. P.; Claessen, D.; Medema, M. H.; Pietruszka, J.; Gross, H. (2018). "Evaluating novel synthetic compounds active against Bacillus subtilis and Staphylococcus aureus biofilms". Scientific Reports. 8 (1): 9171. doi:10.1038/s41598-018-27529-4. PMC 6003959. PMID 29907745.
This article "Pyxis Discovery" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Pyxis Discovery. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
